NCI   NIH
Mouse Models of Human Cancers Consortium
Search: 
Site Map
Gastrointestinal Cancer Models Site Navigation  
1.0 Human Colorectal Cancer
1.1 Development and Biology of the Gastrointestinal system
1.2 Tumor Classification and Staging
1.3 Molecular Alterations
1.4 Novel Therapeutics
2.0 Murine Intestinal Neoplasia
2.1 Murine Models of Colorectal Cancer
2.2 Classification of Murine Intestinal Tumors
Contributors
References
Resources  
1. Gastrointestinal Cancer Models Publications (PubMed)  Opens in New Window: 1. Gastrointestinal Cancer Models Publications (PubMed)
2. Gastrointestinal SPOREs  Opens in New Window: 2. Gastrointestinal SPOREs
3. Gastrointestinal Cancer Models (MMHCC)  Opens in New Window: 3. Gastrointestinal Cancer Models (MMHCC)
4. Gastrointestinal Cancer Models (MMHCC Repository)  Opens in New Window: 4. Gastrointestinal Cancer Models (MMHCC Repository)
5. Intestine Cancer Models (MTB)  Opens in New Window: 5. Intestine Cancer Models (MTB)
6. Intestine Cancer Metastases Models (MTB)  Opens in New Window: 6. Intestine Cancer Metastases Models (MTB)
7. Digestive System Cancer Models (MTB)  Opens in New Window: 7. Digestive System Cancer Models (MTB)
8. Digestive System Cancer Metastases Models (MTB)  Opens in New Window: 8. Digestive System Cancer Metastases Models (MTB)
9. Colon Cancer Chemoprevention Potency Database  Opens in New Window: 9. Colon Cancer Chemoprevention Potency Database

skip top level navigationHome Mouse Models Experimental Therapeutics Resources MMHCC Communication Bioinformatics Learning Tools  

  Emice  >  Mouse Models  >  Organ Site Models  >  Gastrointestinal Cancer Models  >  Human Colorectal Cancer :

Human Colorectal Cancer

GI Development and Biology

The development of the gastrointestinal system is initiated during gastrulation with the formation of the primitive gut. The gastrointestinal system begins as an endoderm-lined tube with three major divisions: the midgut, which opens into the yolk sac; the foregut, which is continuous with the midgut and extends cranially behind the heart; and the hindgut, which extends caudally from the midgut. Gastrulation begins at approximately day 17 of human gestation and at day 7 in the mouse, and by day 22 (day 8 in the mouse) the gut tube is largely closed. The foregut gives rise to the pharynx, lower respiratory tract, liver, gall bladder, pancreas, esophagus, stomach, and the duodenum proximal to the opening of the bile duct. The midgut gives rise to the small intestine (including the duodenum distal to the opening of the bile duct), the cecum, appendix, ascending colon and the proximal part of the transverse colon. The derivatives of the hindgut are the distal part of the transverse colon, the descending and sigmoid colon, the rectum, superior portion of the anal canal, the epithelium of the urinary bladder and most of the urethra (11,12).

Rapid elongation and movements of the midgut that occur between the sixth and tenth week of gestation establish the adult orientation of the large and small intestines. By the beginning of the sixth week (day 10 for mouse embryos), the midgut projects into the umbilical cord. While within the umbilical cord, the midgut loop rotates 90 degrees bringing the cranial limb of the loop to the right and the caudal loop to the left. During this rotation, coiling and elongation of the midgut forms the loops of the small bowel (jejunum and ileum). During the tenth week (days 15-16 for mouse embryos), the intestine undergoes a further 180-degree rotation as it returns to the abdomen, establishing the ultimate position of the ascending, transverse and descending colon with respect to the small intestine (11,12).

The overall histological organization of the digestive system is similar throughout the length of the tract. The lumen is lined with a mucosa that consists of: epithelium with glandular invaginations; a supporting layer of loose connective tissue, the lamina propria; and an underlying layer of smooth muscle, the muscularis mucosae. Submucosal connective tissue surrounds the mucosa and, in the esophagus and duodenum, contains mucus-secreting glands. Two layers of smooth muscle, the inner circular layer and the outer longitudinal layer, make up the muscularis externa that surrounds the submucosa. A simple squamous epithelium, the serosa, covers the outer surface of the wall except at places where the wall is attached by connective tissue to neighboring structures. The enteric nervous system consists of the submucosal plexus and the myenteric plexus that lies between the circular and longitudinal layers of the muscularis externa. The epithelial lining of most of the digestive tract is derived from the endoderm of the primitive gut. The muscular and connective tissue components are derived from the splanchnic mesenchyme surrounding the primitive gut (13,14).

Several anatomical and histological features distinguish the large intestine from other regions of the digestive tract. There are no villi and plicae circulares, thus the luminal surface of the mucosa in the colon is smooth, but when the colon is undistended the mucosa and submucosa exhibit numerous temporary folds. In addition, lymphoid aggregates of varying sizes are located in the lamina propria and submucosa of the colon wall. The epithelium of the large intestine contains numerous goblet cells that secrete mucus to lubricate the lumen and facilitate passage of hardened feces.

For reviews on the molecular basis of gastrointestinal system development see references 15-19.

For additional information about the development and function of the gastrointestinal system see:
http://www.med.unc.edu
http://calloso.med.mun.ca



Tumor Classification and Staging

The classification of tumors is based on the microscopic appearance of hemotoxylin and eosin-stained tumor sections. The World Health Organization (WHO) tumor classification system is the most widely accepted schema for the histologic typing of CRC tumors.

WHO Histologic Classification of Tumors of the Colon and Rectum
(Reprinted from Reference 20)

1. Epithelial tumors
    1.1 Adenoma
        1.1.1 Tubular
        1.1.2 Villous
        1.1.3 Tubulovillous
        1.1.4 Serrated
    1.2 Intraepithelial neoplasia (dysplasia) associated with chronic
inflammatory diseases
        1.2.1 Low-grade glandular intraepithelial neoplasia
        1.2.2 High-grade glandular intraepithelial neoplasia
    1.3. Carcinoma
        1.3.1 Adenocarcinoma
        1.3.2 Mucinous adenocarcinoma
        1.3.3 Signet-ring cell carcinoma
        1.3.4 Small cell carcinoma
        1.3.5 Squamous cell carcinoma
        1.3.6 Adenosquamous carcinoma
        1.3.7 Medullary carcinoma
        1.3.8 Undifferentiated carcinoma
    1.4 Carcinoid (well-differentiated endocrine neoplasm)
        1.4.1 EC-cell, serotonin-producing neoplasm
        1.4.2 L-cell, glucagons-like peptide and PP/PYY- producing tumor
        1.4.3 Others
    1.5 Mixed carcinoid-adenocarcinoma
    1.6 Others
2. Non-epithelial tumors
    2.1 Lipoma (benign)
    2.2 Leiomyoma (benign)
    2.3 Gastrointestinal stromal tumor
    2.4 Leiomyosarcoma
    2.5 Angiosarcoma
    2.6 Kaposi sarcoma
    2.7 Malignant melanoma
    2.8 Others
    2.9 Malignant lymphomas
        2.9.1 Marginal zone B-cell lymphoma of MALT Type
        2.9.2 Mantle cell lymphoma
        2.9.3 Diffuse large B-cell lymphoma
        2.9.4 Burkitt lymphoma
        2.9.5 Burkitt-like/atypical Burkitt-lymphoma
        2.9.6 Others
3. Secondary tumors
4. Polyps
    4.1 Hyperplastic (metaplastic)
    4.2 Peutz-Jeghers
    4.3 Juvenile

CRC can arise spontaneously or in the context of hereditary predispositions such as familial adenomatous polyposis coli (FAP) or HNPCC (also called Lynch I [colon only] and Lynch II [colonic and extracolonic involvement] Syndromes). CRC can also arise from dysplasia in ulcerative colitis. The vast majority of CRCs are adenocarcinomas. Approximately 75% are located in the colon and 25% are located in the rectum (i.e., below the peritoneal reflection). The distinction between these two anatomic locations of the primary tumor is important because of the implications regarding venous drainage and predominant sites of metastases (e.g., liver for colon; lung for rectum) and the need for additional local therapy following surgical resection (e.g., chemotherapy with radiotherapy for locally advanced rectal cancer vs. chemotherapy alone for colon cancers). Non-epithelial tumors such as lymphomas, endocrine tumors, and mesenchymal tumors are only rarely found in the colon and rectum. A thorough description of the internationally recognized standard for histological and genetic classification of colorectal tumors is presented in Hamilton et al. 2000 (20).

CRCs vary in their macroscopic features depending on their location in the colon or rectum and the stage of the lesion. Carcinomas occurring in the right colon or cecum tend to be bulky exophytic masses, while those in the left colon are often endophytic and constricting and may produce colonic obstruction. Those with exophytic growth may be pedunculated, and attached to the underlying wall by a narrow stalk, or sessile. Signet ring cell carcinomas typically produce a linitis plastica growth pattern, in which the tumor diffusely infiltrates the bowel wall, with only subtle thickening of the bowel on gross examination. Carcinomas arising in ulcerative colitis often arise in plaque-like areas of dysplasia, and exhibit predominantly endophytic growth.

The main precursor lesion of sporadic CRCs is the adenoma. Adenomas vary greatly in size and, while most are polypoid, depressed and flat lesions also occur. Microscopically, adenomas consist of columnar epithelial cells with elongated, hyperchromatic, crowded nuclei, with loss of the normal maturation gradient of the crypt. Typical adenomas are considered low-grade dysplastic lesions in which nuclear polarity of the neoplastic cells is maintained with respect to the basement membrane. Progression along the adenoma-carcinoma sequence is often reflected in morphologic changes. In high-grade dysplasia, neoplastic cells are confined by the basement membrane to an intact glandular space but show features of tumor progression such as cytologic features of malignancy, loss of nuclear polarity, and formation of complex glandular outlines. Foci of Paneth cell, goblet cell, and neuroendocrine cell differentiation may be seen in adenomas.

Aberrant Crypt Focus from human colon stained with methylene blue. Single crypt adenomas, readily identifiable by the increase in nucleus to cytoplasm ratio and nuclear crowding and hyperchromasia, may be found in histological sections of grossly normal mucosa in individuals with familial adenomatous polyposis coli.

The typical sporadic CRC consists of large cribiform glands lined by tall columnar tumor cells infiltrating a desmoplastic stroma. Invasion of the neoplastic cells into the submucosa and deeper layers of the bowel wall is necessary for a diagnosis of invasive carcinoma. Lesions that are similar morphologically, but are confined to intact glandular structures or extend only into the lamina propria, have little to no risk of metastasis and are referred to as high grade dysplasia, intramucosal carcinoma, or intramucosal neoplasia. Most CRCs are well to moderately differentiated adenocarcinomas, with few solid areas. Poorly differentiated adenocarcinomas have less than 50% recognizable gland formation.

Grading of Colorectal Carcinomas
Grading of colorectal adenocarcinomas is subjective and is thus subject to interobserver variation. Multiple grading schemes have been proposed, and there is currently no consensus agreement. The basis of assignment of grade is controversial, with some pathologists basing grade on overall impression, some on the worst area of the tumor, some on the amount of gland formation, and some on a combination of features such as gland formation and nuclear grade (Compton CC, Fielding P, Burgart LJ, et al. Prognostic factors in colorectal cancer: College of American Pathologists consensus statement. Arch Pathol Lab Med 124: 979-994, 2000).

The Association of Directors of Anatomic and Surgical Pathology has published recommendations for the reporting of resected colorectal carcinomas (2). Their system is based on a modification of the WHO classification and is recommended only for adenocarcinomas of no special type:

Grade Description
Well differentiated Complex or simple tubules; nuclear polarity maintained; minimal nuclear pleomorphism
Moderately differentiated Complex, simple, or slightly irregular tubules; loss of nuclear polarity
Poorly differentiated Highly irregular glands; solid areas indicating loss of glandular differentiation; loss of nuclear polarity

Some groups recommend using a two-tiered grading system formed by collapsing well and moderately differentiated categories into a single category of low grade, and defining poorly differentiated and undifferentiated tumors as high grade. This two-tiered system retains prognostic significance and has the advantage of better reproducibility.

Some of the special types of carcinoma should not be graded by these schemes. For instance, medullary carcinoma has a solid growth pattern with little glandular differentiation (3) but generally has a more favorable prognosis than high grade adenocarcinoma, NOS. It may not be appropriate to grade mucinous carcinomas.

Typical colorectal adenocarcinoma composed of cribriform glands, often with luminal necrosis. Adenocarcinomas arising in ulcerative colitis often invade the colon wall without forming an exophytic mass.

Several histopathological types of colorectal carcinoma are recognized. Mucinous adenocarcinoma is a morphologic subtype of colorectal carcinoma in which, greater than 50% of the lesion is composed of mucin. These tumors, also called colloid carcinoma, contain large pools of extracellular mucin. Mucinous carcinomas are most often located in the proximal colon. Another variant, signet-ring carcinoma, also produce abundant mucin that is intracytoplasmic rather than extracellular. Medullary carcinoma is characterized by a solid growth pattern, relatively little nuclear pleomorphism, and expansive rather than infiltrative growth, and frequently exhibits microsatellite instability.

Medullary carcinoma characterized by tumor cell growth in sheets, with minimal gland formation. Tumor infiltrating lymphocytes are prominent. Mucinous carcinoma characterized by large pools of extracellular mucin.
Mucinous carcinoma with clusters and strips of tumor cells within the mucin pools. Signet-ring cell carcinomas are composed of cells that accumulate intracytoplasmic mucin and infiltrate the stroma in strands or as single cells, with little gland formation.

Small-cell undifferentiated carcinoma is a rare but highly aggressive neoplasm that is most often widely metastatic at presentation. It is characterized by cells with scant cytoplasm with some signs of neuroendocrine differentiation. Other rare subtypes of human colorectal carcinoma that have been reported in small series or case reports include: spindle cell, pleomorphic (giant cell), pigmented, clear cell, stem cell and Paneth cell-rich (crypt cell) carcinoma, and carcinoma with choriocarcinoma. Mixtures of histopathological subtypes are also observed.

Tumor stage is the most important factor influencing the prognosis of CRC. Two staging systems are commonly used: one is the American Joint Commission on Cancer (AJCC) staging system - based on TNM classification of tumors - that divides colorectal cancers into Stages I, II, III, and IV and the other is the Dukes' staging system that categorizes colorectal cancers into Stages A, B, C, and D. Stage I (Dukes' Stage A) cancers have not spread beyond the mucosa into the submucosa or muscularis propria. Stage II (Dukes' Stage B) cancers have invaded through the muscularis propria and into neighboring tissues (fat or other organs). Stage III (Dukes' Stage C) cancers have spread to local lymph nodes. Stage IV (Dukes' Stage D) cancers have metastasized to distant organs.

TNM Classification of tumors of the colon and rectum (AJCC 2002 TNM System)


T - Primary Tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues
T4 Tumor directly invades other organs or structures and/or perforates visceral peritoneum

N - Regional Lymph Nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1 to 3 regional lymph nodes
N2 Metastasis in 4 or more regional lymph nodes

M - Distant Metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis

Stage Grouping-TNM Subsets

Stage 0TisN0M0
Stage IT1N0M0
 T2N0M0
Stage IIaT3N0M0
Stage IIbT4N0M0
Stage IIIaT1 or T2N1M0
Stage IIIbT3 or T4N1M0
Stage IIIcAny TN2M0
Stage IVAny TAny NM1




Table 4. Histopathological Classification of Human Intestinal Tumors
and Representative Mouse Models.
Human Colorectal Tumor Comments Equivalent Mouse Model
Adenocarcinoma Most common type; sporadic, & inherited predisposition in FAP Apcmin+/-,
Mlh1-/- Apc1638N/+
Msh6-/- Apc1638N/+
Msh3-/- Apc1638N/+
Mucinous carcinoma Mucinous component > 50%; associated with HNPCC and microsatellite instability high tumors Tgfb1-/- Rag2-/-
Smad3-/-
Signet ring cell carcinoma >50% signet ring cells Smad4+/-
Apc Δ716/+
Adenosquamous carcinoma Rare; pure squamous cell carcinoma is very rare Not reported
Small cell undifferentiated carcinoma Neuroendocrine differentiation; highly aggressive Not reported
Undifferentiated carcinoma At least 70% solid growth pattern Not reported
Medullary carcinoma Solid or trabecular growth pattern; little mucin production; tumor-infiltrating lymphocytes; no evidence of neuroendocrine differentiation; HNPCC Not reported


Molecular Alterations in CRC

The APC/Wnt Pathway The APC gene was initially identified by positional cloning of the FAP locus (21,22), and was subsequently found to be mutated in the majority of sporadic colorectal tumors as well. APC is a large (312 kDa), multifunctional intracellular protein; thus its inactivation leads to CRC through multiple molecular mechanisms (reviewed in 23-25).

One important function of APC is its regulatory role in the Wingless/Wnt signaling pathway. APC is part of a protein complex that phosphorylates β-catenin, which marks it for ubiquitination and subsequent proteolytic degradation. In the presence of the WNT signal, or in the absence of APC, the complex is destroyed and β-catenin is stabilized and transported to the nucleus. Inactivation of the APC gene, thus, effectively leads to constitutive activation of the WNT pathway and, consequently, the accumulation of β-catenin in the nucleus. In the nucleus,β-catenin complexes with DNA-binding proteins of the T-cell factor (TCF) family and acts as a co-activator of transcription of several genes involved with proliferation, apoptosis and cell-cycle progression including MYC, cyclin D, matrilysin, CD44 and the urokinase-type plasminogen activator receptor (26-29). Altered expression of these downstream targets of the β-catenin signaling pathway has been implicated in tumor progression, invasion and metastasis.

APC inactivation may also contribute to tumor progression by promoting chromosomal instability (CIN). APC has two identified functions in mitosis: the promotion of proper attachment of the kinetochore to the mitotic spindle and the regulation of centrosome duplication via interactions with tubulin and the centrosome (30). Two types of chromosomal abnormalities are often observed in APC-deficient cells: quantitative effects (tetraploidy) due to non-disjunction, and chromosomal translocations due to multipolar spindles (31). CIN leads to an accumulation of additional mutations that accelerates malignant progression (24).

The TGFβ Pathway There are several lines of evidence suggesting that alterations in the TGFβ signaling pathway play a role the development of CRC. Cell lines derived from human colon tumors are often resistant to the growth-inhibitory effects of TGF-β1, and this resistance is associated with increased invasiveness (32,33). Mutations in TGFβ receptor type II (TGFβRII) are present in both sporadic and inherited colon cancers that exhibit microsatellite instability (34-36). Inactivating mutations in SMAD2 and SMAD4, that encode intracellular proteins involved in the transduction of the TGFβ signal, are also present in human colon cancer (37-39).

TGFβ signaling is multifunctional; consequently there are several mechanisms by which the loss of TGFβ function could contribute to the initiation, promotion or progression of CRC. TGFβ1 inhibits epithelial cell growth in vitro and the absence of this inhibition may enhance tumor cell proliferation in vivo. In addition, TGFβ plays a role in remodeling of the extracellular matrix; thus the disruption of TGFβ function may also lead to the dysregulation of tumor cell-matrix interactions and epithelial cell differentiation (40). Lastly, TGFβ1 is a potent regulator of immune and inflammatory cell responses and the disruption of this function could lead to a lack of inhibition of the local production of growth factors as well as tissue damage induced by free radicals (41).

DNA Mismatch Repair Deficiency The MMR system in cells functions to correct mismatched base pairs and insertion/deletion loops that arise during DNA synthesis. HNPCC is caused by an inherited mutation in any one of the five human MMR genes; MSH2, MLH1, MSH6, PMS2 and PMS1 (42). In HNPCC, MMR gene inactivation results from germline mutation of one allele, followed by LOH of the second allele. Microsatellite instability (MSI), an indicator of MMR deficiency, occurs in essentially all HNPCC-related tumors, and approximately 15% of sporadic tumors. In sporadic tumors with MSI, MMR deficiency is due to an epigenetic mechanism, hypermethylation of the promoter region of a single MMR gene, MLH1 (10).

Dysfunction of the MMR system affects important growth-regulatory genes that are known to be involved in the development of colorectal tumors (e.g. APC, K-RAS and p53), and genes with mononucleotide repeats in their coding regions (e.g. TGFbRII, insulin-like growth factor II receptor , and BAX, a proapoptotic gene) are particularly vulnerable to increased mutation rates (43-45). MMR proteins have other functions related to DNA damage signaling and apoptosis that may also be relevant to tumorigenesis (reviewed in 42).

Tumors with a high frequency of MSI (termed MSI-high) exhibit histologic features of aggressive tumors but are paradoxically associated with a significant survival advantage that is independent of tumor stage or lymph node involvement (46). Certain histologic subtypes, such as medullary carcinoma and mucinous carcinoma, are over-represented among MSI-high tumors.



Novel Therapeutics

Fluorouracil (5-FU) was for many years the only effective chemotherapy drug for CRC, however, primary resistance to 5-FU is observed in approximately 30% of patients with metastatic colorectal cancer and nearly all patients will ultimately develop secondary resistance. In recent years, new therapeutic options have emerged (such as Mitomycin C (MMC), oxaliplatin, irinotecan, and oral fluoropyrimidines such as capecitabine that enhance the efficacy of 5-FU when used in combination chemotherapy regimens. With the availability of new drugs with activity against CRC, many current randomized trials are focused on comparing different combination chemotherapy regimens to optimize the balance between efficacy and toxicity.

MMC (an inhibitor of DNA synthesis), like irinotecan, was initially identified for use as second-line therapy. Recently, MMC has been evaluated as first-line treatment for advanced CRC in combination with 5-FU in a phase III clinical trial and shown to be superior with respect to response rates and overall survival to 5-FU alone (47).

Oxaliplatin (LOHP, Eloxatine) is a platinum analog that binds to guanine residues of DNA and interferes with DNA replication and transcription. While still controversial, preliminary studies have shown that combination therapy with 5-FU, leucovorin, and irinotecan (IFL) or oxaliplatin is more active than 5FU, and leucovorin alone (48). Results of a large randomized trial of oxaliplatin, 5-FU and leucovorin combination therapy in patients with CRC that has relapsed after first-line IFL are expected in the fall of 2002. Oxaliplatin is currently under review by the US Food and Drug Administration and, if found to be sufficiently safe and effective, may become commercially available in the United States by the end of the year.

Agents that disrupt the molecular pathways of carcinogenesis have the potential to direct cellular toxicity to the tumor while sparing normal cells. With increased understanding of these pathways, biological therapies that specifically target them are becoming increasingly prevalent in clinical trials of new CRC treatments. One example involves agents that block the signaling activity of the epidermal growth factor (EGF) receptor. The EGF receptor (EGFR) is overexpressed in many epithelial tumors and its level of expression is inversely correlated with survival (49). Phase I/II trials have shown that C225, a monoclonal antibody that blocks EGFR function, in combination with chemotherapy, has activity against chemotherapy-resistant cancers (50). ZD1839 (Iressa), a pharmacological inhibitor of EGFR tyrosine kinase activity, is currently being tested in a phase II clinical trial.

The prevention of tumor angiogenesis is another important therapeutic strategy that is being tested in many types of cancer. Vascular endothelial growth factor (VEGF) plays an important role in normal and tumor angiogenesis. A recent phase II study suggests that a monoclonal antibody against VEGF in combination with chemotherapy has greater efficacy in treating metastatic CRC compared to chemotherapy alone (51).

Cyclooxygenase (COX) converts arachidonic acid into prostaglandins and other prostanoids that enhance carcinogenesis by promoting cell proliferation, inhibiting apoptosis, and promoting tumor angiogenesis (reviewed in 52). The COX-2 isoform is overexpressed in a wide variety of neoplasms, including CRC (53). Targeted disruption of the COX-2 gene in APCD716 mice (a model for FAP) reduced the number and size of intestinal polyps by nearly 80% (54), providing a dramatic demonstration of the causal relationship between COX-2 and colorectal tumorigenesis. Recent human studies have shown that COX-2 inhibitors can prevent polyps in FAP patients (55).

Preliminary data from a multi-center phase II trial of STI571 (Gleevec), an inhibitor of the BCR-ABL tyrosine kinase and the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and c-kit, suggests that this drug is efficacious for treating patients with unresectable or metastatic gastrointestinal stromal tumors (GIST; 56). Other novel agents with potential activity against CRC that are currently in clinical trials include immunotherapy agents to stimulate immune rejection of residual tumor cells and farnesyl transferase inhibitors, which prevent Ras activation (reviewed in 57).

For a more complete listing of drugs currently in development and ongoing clinical trials see: http://www.cancer.gov/search/clinical_trials/


CONTACT US PRIVACY NOTICE DISCLAIMER ACCESSIBILITY APPLICATION SUPPORT  
National Cancer Institute Department of Health and Human Services National Institutes of Health FirstGov.gov